Cartesian Therapeutics, Inc. — Filing Summary
Filing identity: The supplied Form 10-Q is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. Investors should verify the issuer before relying on this summary.
Business Context and Reporting Period
Selecta was a clinical-stage biotechnology company developing tolerogenic therapies using its ImmTOR platform. Its programs addressed biologic therapies, gene therapies and autoimmune diseases. The unaudited reporting period covered the three months ended March 31, 2023, with comparison to the three months ended March 31, 2022.
The company had no approved products and generated no product-sales revenue. Revenue primarily came from collaboration and license arrangements, including agreements with Sobi, Astellas, Takeda and Sarepta.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Collaboration and license revenue | $5.9 million | $34.0 million | Down 83% |
| Research and development expense | $18.6 million | $17.7 million | Up 5% |
| General and administrative expense | $5.7 million | $5.5 million | Up 3% |
| Total operating expenses | $24.3 million | $23.2 million | Up 5% |
| Operating loss | $18.4 million | Operating income of $10.8 million | Material deterioration |
| Net loss | $21.7 million | Net income of $28.8 million | Material deterioration |
| Basic loss per share | $0.14 loss | $0.23 income | Not comparable in direction |
| Net cash used in operating activities | $8.8 million | $11.9 million | Use decreased $3.1 million |
Q1 2023 net loss included a $4.1 million non-cash charge from the increase in the fair value of warrant liabilities. Q1 2022 included an $18.5 million non-cash gain from warrant revaluation, significantly affecting the year-over-year earnings comparison.
Cash, cash equivalents and restricted cash totaled $127.5 million at March 31, 2023, including $1.6 million of restricted cash related to lease commitments and $0.2 million held by the Russian subsidiary for operational use. Cash and cash equivalents were $125.9 million. Marketable securities declined to zero from $28.2 million at December 31, 2022, primarily because securities matured and proceeds were converted to cash.
Total debt was approximately $26.4 million, consisting primarily of the $25.0 million principal balance under the 2020 term loan, plus fees and debt discount adjustments. The term loan was scheduled to mature in August 2025, with $25.0 million of minimum principal payments remaining.
Stockholders’ equity declined to $74.6 million from $93.8 million at December 31, 2022, primarily due to the quarterly net loss. The accumulated deficit was $416.6 million.
Material Changes Versus the Prior Comparable Period
- Revenue decreased by $28.1 million, primarily because Q1 2022 included $9.2 million recognized upon termination of the Spark agreement and substantially higher Sobi-related revenue.
- Q1 2023 revenue included $4.4 million from Sobi, $0.6 million from Astellas, $0.5 million from Takeda and $0.5 million from Sarepta.
- Astellas paid a $10.0 million upfront amount in January 2023 for rights relating to Xork. The company recognized $0.6 million of related revenue during the quarter and recorded $9.6 million of deferred revenue at March 31, 2023.
- The company paid Genovis $4.0 million in February 2023 in connection with the sublicense of Xork to Astellas.
- Sarepta notified the company in March 2023 that it would not exercise its exclusive option; the remaining $0.5 million of deferred revenue was recognized in Q1 2023.
- Takeda notified the company in April 2023 of its intention to terminate its agreement effective July 25, 2023.
- Research and development expense increased due primarily to contract license and milestone payments and personnel costs, partly offset by lower SEL-212 clinical-program spending.
- The company entered into a fourth amendment to its term loan agreement following the March 2023 failure and resolution of Silicon Valley Bank. The amendment changed collateral-account requirements.
Guidance, Outlook, Risks and Unusual Items
In April 2023, management paused further development of SEL-302 for methylmalonic acidemia and announced a targeted headcount reduction of approximately 25% to extend the cash runway. The company estimated approximately $1.0 million of 2023 cash charges for severance and benefits.
Management stated that cash, cash equivalents and restricted cash at March 31, 2023 would fund current planned operations for at least the next twelve months. In the MD&A, following strategic reprioritization and assuming an anticipated SEL-212 milestone payment, management estimated funding into the second half of 2025. These estimates are subject to execution, clinical, regulatory, collaboration and financing risks.
Management expects operating losses to continue for the foreseeable future and may seek additional funding through equity or debt financings, collaborations, licensing transactions, or potential monetization of milestone and royalty rights. Additional financing may be dilutive or unavailable on favorable terms.
- Key clinical and regulatory risks include failure to enroll or complete trials, unfavorable results, manufacturing constraints and inability to obtain approvals.
- Revenue is dependent on collaboration milestones, reimbursements and license arrangements and may fluctuate materially between periods.
- Takeda’s planned termination and Sarepta’s decision not to exercise its option may reduce future collaboration opportunities and revenue.
- The company remains exposed to warrant-liability valuation volatility, which can materially affect reported earnings without directly affecting cash.
- Debt is secured by substantially all assets other than intellectual property, subject to the terms of the loan agreement and customary events of default.
- The filing reported no material litigation, no off-balance-sheet arrangements and no material changes to previously disclosed risk factors.
Investor Verification Checklist
- Confirm whether this filing belongs to Selecta Biosciences or Cartesian Therapeutics; the supplied document identifies Selecta throughout.
- Verify the effect of the April 2023 SEL-302 pause and 25% workforce reduction on future research spending and clinical plans.
- Assess the likelihood and timing of the anticipated SEL-212 milestone payment supporting the runway estimate through the second half of 2025.
- Review the consequences of Takeda’s planned termination and the loss of Sarepta’s exclusive option.
- Reconcile collaboration revenue, deferred revenue and remaining performance obligations of $9.8 million.
- Monitor cash burn, the $25.0 million term loan repayment schedule and potential need for additional capital.
- Evaluate dilution risk from approximately 31.2 million outstanding warrants, 20.6 million outstanding employee stock options and other reserved shares.